Literature DB >> 20040351

Relation between polymorphisms of receptor for advanced glycation end products (RAGE) and cardiovascular diseases in Chinese patients with diabetic nephropathy.

P Y-K Poon1, C-C Szeto, K-M Chow, B C-H Kwan, P K-T Li.   

Abstract

BACKGROUND: Interaction of receptor for advanced glycation end products (RAGE) with advanced glycation end products (AGEs) is an important pathogenic mechanism of diabetic complications. Three mutations in the promoter region of the RAGE gene (T-429C, T-374A and a 63 bp deletion spanning from -407 to -345 nucleotides) were known to have increased transcriptional activities. We investigated the relationship between these polymorphisms and the risk of cardiovascular diseases in Chinese subjects with overt diabetic nephropathy.
METHODS: A total of 219 Type 2 diabetic subjects with nephropathy were recruited. Genotyping of the three polymorphisms in the genomic DNA was done by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Patients were followed for 8 years for the development of cardiovascular events and survival.
RESULTS: The T-429 C and T-374 A polymorphism had no effect on the event-free survival of the subjects. For the 63 bp deletion polymorphism, the event-free survival was 37.0% and 63.2% at 96 months for del-/- and del-/+ genotypes, respectively (log-rank test, p = 0.034). After adjusting for confounders, the 63 bp deletion polymorphism had a marginal effect on event-free survival (adjusted hazard ratio: 3.517, 95% CI: 0.852 - 14.521, p = 0.082). Subjects without any mutation of the three polymorphisms have significantly higher risk of first ischemic heart disease than those with any of the three mutations (adjusted hazard ratio: 0.218, 95% CI: 0.062 - 0.764, p = 0.017).
CONCLUSION: The 63 bp del-/+ genotype of the RAGE gene has a marginal benefit on the cardiovascular event-free survival in subjects with diabetic nephropathy. Subjects with any of the three mutations have a lower risk of ischemic heart disease. The role of RAGE in the pathogenesis of cardiovascular disease in diabetic patients requires further study.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20040351     DOI: 10.5414/cnp73044

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  4 in total

1.  Relationship between RAGE gene polymorphisms and cardiovascular disease prognosis in the Chinese Han population.

Authors:  Jinxiong Gao; Liehua Deng; Ying Wang; Yanke Shi; Xiaohua Xiao; Xueou Zheng; Hao Ren; Dingli Xu
Journal:  Mol Genet Genomics       Date:  2017-06-28       Impact factor: 3.291

Review 2.  Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure.

Authors:  Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Curr Heart Fail Rep       Date:  2012-06

Review 3.  Pathological Implications of Receptor for Advanced Glycation End-Product (AGER) Gene Polymorphism.

Authors:  Marine Serveaux-Dancer; Matthieu Jabaudon; Isabelle Creveaux; Corinne Belville; Raïko Blondonnet; Christelle Gross; Jean-Michel Constantin; Loïc Blanchon; Vincent Sapin
Journal:  Dis Markers       Date:  2019-02-04       Impact factor: 3.434

4.  Association of the receptor for advanced glycation end-products (RAGE) gene polymorphisms in Malaysian patients with chronic kidney disease.

Authors:  Foo Nian Wong; Kek Heng Chua; Umah Rani Kuppusamy; Chew Ming Wong; Soo Kun Lim; Jin Ai Mary Anne Tan
Journal:  PeerJ       Date:  2016-04-18       Impact factor: 2.984

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.